Trial reportJournal of child and adolescent psychopharmacology2009
Metformin for weight control in pediatric patients on atypical antipsychotic medication.
Trial report in Journal of child and adolescent psychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis.CNS drugs · 2018Pooled it
- Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis.BMC psychiatry · 2016 · on this mapPooled it
- Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.British journal of clinical pharmacology · 2011 · on this mapPooled it
- A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics.Journal of pediatric endocrinology & metabolism : JPEM · 2011Trial
- Clozapine in Child and Adolescent Psychiatry.Paediatric drugs · 2026Article
- Article
- The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.Frontiers in psychiatry · 2021Review
- Strategies in the Management of Adolescent Obesity.Current pediatrics reports · 2020Article
- Second generation antipsychotic-induced weight gain in youth with autism spectrum disorders: a brief review of mechanisms, monitoring practices, and indicated treatments.International journal of developmental disabilities · 2019Review
- Metformin for Antipsychotic-Related Metabolic Syndrome in Children: Fact or Fiction?Chinese medical journal · 2018Article
- Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2015Article
- Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia.Psychopharmacology · 2013Review
- [Not Available].Paediatrics & child health · 2012Article
- Psychological issues in pediatric obesity.Industrial psychiatry journal · 2012Article
- Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth.Paediatrics & child health · 2011Article
- Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveMetformin was assessed as an interventional medication for weight gain in children and adolescents taking atypical antipsychotic agents.
methodA 12-week open-label trial was conducted to evaluate metformin's effectiveness and safety for weight management. Eleven subjects, ages 10-18 years, participated in the study. Each subject received metformin orally up to 2000 mg/day. Primary outcome measures included weight, body mass index (BMI), and waist circumference. Secondary outcome measures included serum glucose, insulin, and fasting lipid profile. Changes in weight, BMI, waist, and metabolic profile were obtained by using repeated measures of covariance.
resultsThe mean reduction in weight, waist, BMI, serum glucose, and serum insulin was not statistically significant. However, 5 out of 11 patients lost weight (mean, -2.82 kg +/- 7.25), and overall the sample did not continue to gain weight. There was a significant decrease in triglyceride levels. Metformin was fairly well tolerated.
conclusionPreliminary data suggests that metformin may safely and effectively improve the triglyceride profile. However, contrary to study hypotheses, weight, waist, and BMI reduction were not statistically significant. Future double-blind studies with larger sample sizes and of longer duration are warranted to assess more fully the safety and efficacy of this intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.